• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

从研究到政策：世界卫生组织在制定关于潜在 HIV 获得风险和单纯孕激素避孕方法使用的指南方面的经验。

From Research to Policy: The WHO Experience With Developing Guidelines on the Potential Risk of HIV Acquisition and Progestogen-Only Contraception Use.

机构信息

Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, USA.

WHO AFRO, Intercounty Support Team for Eastern and Southern Africa, Harare, Zimbabwe.

出版信息

Glob Health Sci Pract. 2017 Dec 28;5(4):540-546. doi: 10.9745/GHSP-D-17-00278.

DOI:10.9745/GHSP-D-17-00278
PMID:29284693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5752602/
Abstract

To develop guidance for women at high risk of HIV, WHO carefully considered the risks of maternal morbidity and mortality from unintended pregnancy against possible increased risk of HIV acquisition with injectable use. Among the many challenges: (1) balancing timeliness of changing the guidance against the potential impact of it; (2) engaging a range of stakeholders; (3) translating complex research and policy messages to clients; (4) needing additional research; and (5) monitoring and evaluating successes and challenges with implementing new guidelines.

摘要

为制定艾滋病毒高风险妇女的指导意见，世卫组织仔细考虑了因意外怀孕而导致产妇发病率和死亡率的风险与注射使用可能增加艾滋病毒感染风险之间的关系。面临的许多挑战包括：（1）平衡指导意见更新的及时性与潜在影响；（2）让广泛的利益攸关方参与；（3）将复杂的研究和政策信息转化为服务对象能够理解的内容；（4）需要开展更多研究；（5）监测和评估实施新准则的成功和挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b4/5752602/57ae7f64d537/GH-GHSP170073F003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b4/5752602/138a1aa20bd1/GH-GHSP170073F001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b4/5752602/fe6f8cb545a2/GH-GHSP170073F002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b4/5752602/57ae7f64d537/GH-GHSP170073F003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b4/5752602/138a1aa20bd1/GH-GHSP170073F001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b4/5752602/fe6f8cb545a2/GH-GHSP170073F002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38b4/5752602/57ae7f64d537/GH-GHSP170073F003.jpg

相似文献

1
From Research to Policy: The WHO Experience With Developing Guidelines on the Potential Risk of HIV Acquisition and Progestogen-Only Contraception Use.从研究到政策：世界卫生组织在制定关于潜在 HIV 获得风险和单纯孕激素避孕方法使用的指南方面的经验。
Glob Health Sci Pract. 2017 Dec 28;5(4):540-546. doi: 10.9745/GHSP-D-17-00278.
2
Guidance on medical eligibility criteria for contraceptive use: identification of research gaps.避孕使用的医学适宜性标准指南：研究差距的识别
Contraception. 2010 Jul;82(1):113-8. doi: 10.1016/j.contraception.2010.02.015. Epub 2010 Mar 31.
3
Hormonal contraception for women exposed to HIV infection.感染艾滋病毒的女性的激素避孕法。
Cochrane Database Syst Rev. 2014 May 20;2014(5):CD009741. doi: 10.1002/14651858.CD009741.pub2.
4
Changes to the World Health Organization guideline on hormonal contraceptive eligibility for women at high risk of HIV: South African perspective and response.世界卫生组织关于艾滋病毒高风险女性激素避孕资格指南的修订：南非视角与应对措施
S Afr Med J. 2018 Jul 25;108(8):629-631. doi: 10.7196/SAMJ.2018.v108i8.13160.
5
Making WHO recommendations more responsive.使世卫组织的建议更具针对性。
Bull World Health Organ. 2014 Nov 1;92(11):778-9. doi: 10.2471/BLT.14.021114.
6
Re-Evaluating the Possible Increased Risk of HIV Acquisition With Progestin-Only Injectables Versus Maternal Mortality and Life Expectancy in Africa: A Decision Analysis.重新评估非洲地区单纯孕激素避孕注射与孕产妇死亡率和预期寿命的关系：决策分析。
Glob Health Sci Pract. 2017 Dec 28;5(4):581-591. doi: 10.9745/GHSP-D-17-00243.
7
Copper containing intra-uterine devices versus depot progestogens for contraception.含铜宫内节育器与长效孕激素用于避孕的比较。
Cochrane Database Syst Rev. 2010 Jun 16;2010(6):CD007043. doi: 10.1002/14651858.CD007043.pub2.
8
Should women with HIV, or at high risk of contracting HIV, use progestogen-containing contraception?
BMJ. 2013 Nov 14;347:f6695. doi: 10.1136/bmj.f6695.
9
Planning for Outcomes (PO) Modeling Tool: Estimating the Impact of Changing the Proportion of Injectable Progestins in the Contraceptive Method Mix.计划生育结局规划模型工具：估计改变避孕方法组合中注射用孕激素比例的影响。
Glob Health Sci Pract. 2019 Jun 27;7(2):317-328. doi: 10.9745/GHSP-D-19-00062. Print 2019 Jun.
10
Acceptance of progestogen-only contraceptives by indigenous women from south Mexico.
Int J Gynaecol Obstet. 2016 Feb;132(2):236. doi: 10.1016/j.ijgo.2015.07.013. Epub 2015 Nov 6.

引用本文的文献

1
From policy to practice: Experiences from the ECHO trial following revisions of the WHO medical eligibility criteria for contraceptive use (MEC) guidance on DMPA-IM.从政策到实践：世界卫生组织关于醋酸甲羟孕酮注射剂（DMPA-IM）的避孕药具使用医学适用性标准（MEC）指南修订后ECHO试验的经验
Contracept X. 2024 Sep 29;6:100111. doi: 10.1016/j.conx.2024.100111. eCollection 2024.
2
Self-administration of injectable contraception: a systematic review and meta-analysis.注射用避孕药的自我给药：一项系统评价与荟萃分析。
BMJ Glob Health. 2019 Apr 2;4(2):e001350. doi: 10.1136/bmjgh-2018-001350. eCollection 2019.
3
Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women.

本文引用的文献

1
Re-Evaluating the Possible Increased Risk of HIV Acquisition With Progestin-Only Injectables Versus Maternal Mortality and Life Expectancy in Africa: A Decision Analysis.重新评估非洲地区单纯孕激素避孕注射与孕产妇死亡率和预期寿命的关系：决策分析。
Glob Health Sci Pract. 2017 Dec 28;5(4):581-591. doi: 10.9745/GHSP-D-17-00243.
2
An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women.关于激素避孕方法与女性感染艾滋病毒情况的流行病学证据的最新系统评价。
AIDS. 2016 Nov 13;30(17):2665-2683. doi: 10.1097/QAD.0000000000001228.
3
Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence.
基于 MPA 和 NET 的孕激素避孕药与 HIV 获得的潜在影响相关的药代动力学、生物学和流行病学差异。
Contraception. 2019 Apr;99(4):199-204. doi: 10.1016/j.contraception.2018.12.001. Epub 2018 Dec 18.
4
The Need for Policy Change Regarding Progestin-Only Injectable Contraceptives.关于仅含孕激素的注射用避孕药的政策变革需求。
J Womens Health (Larchmt). 2019 Sep;28(9):1180-1184. doi: 10.1089/jwh.2018.7284. Epub 2018 Dec 21.
激素避孕方法与女性感染艾滋病毒的风险：流行病学证据的系统综述
Contraception. 2014 Oct;90(4):360-90. doi: 10.1016/j.contraception.2014.07.009. Epub 2014 Jul 23.
4
Progestin-only contraception: injectables and implants.仅含孕激素的避孕方法：注射剂和植入剂。
Best Pract Res Clin Obstet Gynaecol. 2014 Aug;28(6):795-806. doi: 10.1016/j.bpobgyn.2014.05.003. Epub 2014 Jun 5.
5
Hormonal contraception and HIV acquisition - what is the evidence? What are the policy and operational implications?
Eur J Contracept Reprod Health Care. 2013 Feb;18(1):15-26. doi: 10.3109/13625187.2012.744819.
6
Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk.建模潜在的注射用激素避孕和 HIV 风险之间相互作用的全球竞争风险。
AIDS. 2013 Jan 2;27(1):105-113. doi: 10.1097/QAD.0b013e32835a5a52.
7
Evaluating the competing risks of HIV acquisition and maternal mortality in Africa: a decision analysis.评估非洲获得性 HIV 感染和孕产妇死亡率的竞争风险：决策分析。
BJOG. 2012 Aug;119(9):1067-73. doi: 10.1111/j.1471-0528.2012.03402.x. Epub 2012 Jun 7.
8
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.激素避孕与 HIV-1 传播风险：一项前瞻性队列研究。
Lancet Infect Dis. 2012 Jan;12(1):19-26. doi: 10.1016/S1473-3099(11)70247-X. Epub 2011 Oct 3.
9
Integrating HIV clinical services into primary health care in Rwanda: a measure of quantitative effects.将卢旺达的艾滋病毒临床服务纳入初级卫生保健：定量效果评估。
AIDS Care. 2009 May;21(5):608-14. doi: 10.1080/09540120802310957.